- CoTherix
-
CoTherix, Inc. 
Former type Subsidiary Industry Pharmaceutical Fate acquired by Actelion Founded 2000 Defunct January 9, 2007 Headquarters South San Francisco, California Key people Donald J. Santel, CEO & Director Products Ventavis Revenue $63 million USD Employees 100 Website www.cotherix.com CoTherix, Inc. was a biopharmaceutical company located in South San Francisco, California. CoTherix focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. The company, formerly known as Exhale Therapeutics, Inc., was founded in February 2000 by Gerard Turino, MD, a past president of the American Thoracic Society, and Jerome Cantor, MD, a pulmonary pathologist.
CoTherix's commercial product was "Ventavis (iloprost)", an inhaled therapy for pulmonary artery hypertension (PAH). It was approved by the United States Food and Drug Administration in December 2004, two months after the company's initial public offering of 5 millions shares of common stock.
CoTherix inlicensed Fasudil from Asahi Kasei and its commercialization rights in the U.S. and Europe.
On November 20 2006, CoTherix agreed to be purchased for $420 million in cash by Actelion of Basel, Switzerland. On January 9, 2007, the deal closed with Actelion paying $13.50 for each share of CoTherix stock.
External links
Categories:- Biotechnology companies
- Pharmaceutical companies of the United States
- Companies based in San Mateo County, California
- Defunct companies based in California
Wikimedia Foundation. 2010.
